Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study

Autor: Radwa Samir Hagag, Morkoss Medhat Fakhry, Ossama Ashraf Ahmed, Shaimaa Abdalaleem Abdalgeleel, Mahasen Aly Radwan, Gina Gamal Naguib
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: The Egyptian Journal of Internal Medicine, Vol 34, Iss 1, Pp 1-9 (2022)
Druh dokumentu: article
ISSN: 1110-7782
2090-9098
DOI: 10.1186/s43162-022-00126-8
Popis: Abstract Background The devastating adverse effects of interferon (IFN) for the treatment of hepatitis C virus (HCV) lead to the emerging of direct acting antiviral agents (DAAs). This investigation was undertaken to assess safety and efficacy of two Egyptian DAA protocols for HCV: sofosbuvir (SOF)/daclatasvir (DCV)/simeprevir (SMV)/ribavirin (RBV) and sofosbuvir (SOF)/ombitasvir (OMB)/paritaprevir (PTV)/ritonavir (RTV)/RBV for 12 weeks in treatment-experienced HCV Egyptian patients. Methods It is a retrospective study where 139 patients, out of 400 patients, were divided according to their documented treatment protocol into two groups (Gp1: SOF/DCV/SMV/RBV and Gp2: SOF/PTV/OMB/RTV/RBV). All patients’ physical examination, disease history, laboratory baseline, and end of treatment data were collected from their profiles, evaluated and compared. Results Gp1 and Gp2 regimens had achieved sustained virologic response rates (SVR12) of 96.6% and 95.1%, respectively. Hemoglobin, ALT, and AST had decreased significantly (P
Databáze: Directory of Open Access Journals
Externí odkaz: